Attached files
| file | filename |
|---|---|
| S-1/A - QUARK PHARMACEUTICALS INC | v208841_s1a.htm |
| EX-10.43 - QUARK PHARMACEUTICALS INC | v208841_ex10-43.htm |
Exhibit
23.3
January
19, 2011
Sagit
Reich
Chief
Financial Officer
Quark
Pharmaceuticals, Inc.
6501
Dumbarton Circle
Fremont,
CA 94555
Subject:
WRITTEN CONSENT TO REFERENCE VARIANCE ECONOMIC CONSULTING VALUATION IN S-1
FILING of QUARK
PHARMACEUTICALS,
INC.
We hereby
consent to the inclusion in the registration statement on Form S-1 of Quark
Pharmaceuticals, Inc. (the "Company") and any amendment thereto (the
"Registration Statement") of references to our final reports to the Board of
Directors of the Company as of various dates relating to the estimation of the
fair value of the common stock of the Company and other equity instruments and
to references to our firm's name therein. We also consent to the references to
us under the Experts Section in the Registration Statement. However, in giving
such consent, we do not admit that we come within the category of person whose
consent is required under Section 7 or Section 11 of the Securities Act of 1933,
as amended, or the rules and regulations adopted by the Securities and Exchange
Commission thereunder, nor do we admit that we are experts with respect to any
part of such Registration Statement within the meaning of the term "experts" as
used in the Securities Act of 1933, as amended or the rules and regulations of
the Securities and Exchange Commission thereunder.
Sincerely,
/s/
VARIANCE ECONOMIC CONSULTING LTD.
VARIANCE
ECONOMIC CONSULTING